Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K)

By Watanabe I.   Hagiwara Y.   Kadowaki S.-e.   Yoshikawa T.   Komase K.   Aizawa C.   Kiyono H.   Takeda Y.   McGhee J.R.   Chiba J.   Sata T.   Kurata T.   Tamura S.-i.  

Vaccine, Vol. 20, Iss. 29, 2002-10 ,pp. : 3443-3455

Elsevier

Access to resources Recommend Favorite

Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin)

By Matsuo K.   Yoshikawa T.   Asanuma H.   Iwasaki T.   Hagiwara Y.   Chen Z.   Kadowaki S.-e.   Tsujimoto H.   Kurata T.   Tamura S.-i.  

Vaccine, Vol. 18, Iss. 24, 2000-06 ,pp. : 2713-2722

Elsevier

Access to resources Recommend Favorite

Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine

By Komase K.   Tamura S.-i.   Matsuo K.   Watanabe K.   Hattori N.   Odaka A.   Suzuki Y.   Kurata T.   Aizawa C.  

Vaccine, Vol. 16, Iss. 2, 1998-01 ,pp. : 248-254

Elsevier

Access to resources Recommend Favorite

A nasal whole-cell pertussis vaccine can induce strong systemic and mucosal antibody responses which are not enhanced by cholera toxin

By Berstad A.K.H.   Holst J.   Mogster B.   Haugen I.L.   Haneberg B.  

Vaccine, Vol. 15, Iss. 12, 1997-08 ,pp. : 1473-1478

Elsevier

Access to resources Recommend Favorite

Mechanism of enhancement of the immune responses to influenza vaccine with cholera toxin B subunit and a trace amount of holotoxin

By Tamura S.-i.   Ishihara K.   Miyata K.   Aizawa C.   Kurata T.  

Vaccine, Vol. 13, Iss. 4, 1995-01 ,pp. : 339-341

Elsevier

Access to resources Recommend Favorite